Press Resease

Neuroblastoma Treatment Market - Global Industry Analysis

Neuroblastoma Treatment Market by Therapy (Surgery, Chemotherapy, Immunotherapy, and Radiotherapy), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Drug Stores): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2028

Published Date: 27-Sep-2021 Category: Medical Device Report Format : PDF Pages: 144 Report Code: ZMR-18 Status : Published

According to analysts at Zion Market Research, the Neuroblastoma Treatment market accounted for USD 437.1 Million in 2020 and is expected to reach USD 600.5 Million by 2028, growing at a CAGR of more than 4.1% from 2021 to 2028.

Description

Market Overview

The neuroblastoma treatment market accounted for USD 437.5 Million in 2020 and is expected to reach USD 600.5 Million by 2028, growing at a CAGR of 4.1% from 2021 to 2028.

Neuroblastoma is a type of pediatric cancer that is developed in the nervous system of babies and young children. It grows in immature nerve tissue known as neuroblasts. It affects the adrenal glands present just above the kidneys. Neuroblastoma can also develop in nerve tissue in the spinal cord, abdomen, chest or neck. It can spread to other parts of the body. Due to the higher rate of neuroblastoma the need for the treatment is necessary in coming years. Increasing population and frequency of this cancer is the prime reason for the treatment for Neuroblastoma and hence there is growth rate for this market is necessary.

Global Neuroblastoma Treatment Market Size

COVID-19 Impact Analysis

According to data gathered from countries such as UK & U.S. the treatment for neuroblastoma was on a halt as young children and babies get affected to corona virus on rapid rate. CCLG, one of the active groups of doctors in UK have also recently published data about children with cancer who have had coronavirus, to provide a clear picture of the impact of the virus on young cancer patients. Based on the information gathered by this project, CCLG’s updated advice includes recommendations for the extremely vulnerable and vulnerable groups. Thus, the market for neuroblastoma was on a steady growth rated due to COVID-19.

Growth Factors

Neuroblastoma is rare cancer but it’s the most common cancer in babies. According to health organization in the United States, about 800 children are diagnosed with neuroblastoma. It almost always develops before age 5. It can occur in babies before they are born. Neuroblastoma is very rare in children over age 10. There are four stages in neuroblastoma such as Stage L1, Stage L2, Stage M, and Stage MS. Neuroblastoma happens when immature nerve tissues (neuroblasts) grow out of control. The cells become abnormal and continue growing and dividing, forming a tumor. A genetic mutation (a change in the neuroblast’s genes) causes the cells to grow and divide uncontrollably. Healthcare providers are not sure what causes the genetic mutation and still there is no technology to find the main cause for this cancer to grow. Due to this reason the need for the treatment is necessary and government bodies and healthcare companies are investing huge funds for research and development for this treatment. In coming years due to higher birthrate the need for this treatment is the major factor concerning the growth for neuroblastoma treatment market.

Report Scope :

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Therapy Segment Analysis Preview

Therapy segment is sub-divided in Surgery, Chemotherapy, Immunotherapy, and Radiotherapy. Surgery segment is one of the major segments that contribute of about 45% in total global revenue for neuroblastoma treatment market, followed by other segments such as chemotherapy, immunotherapy and radiotherapy. Surgery is the removal of the tumor and some surrounding healthy tissue during an operation. A surgical oncologist is a doctor who specializes in treating cancer using surgery. If the cancer has not spread, surgery can sometimes be used to remove the entire tumor. Chemotherapy is the use of drugs to destroy cancer cells, usually by ending the cancer cells’ ability to grow and divide. Chemotherapy is given by a pediatric oncologist or a medical oncologist, a doctor who specializes in treating cancer with medication. Radiotherapy is the use of high-energy x-rays or other particles to destroy cancer cells.

Global Neuroblastoma Treatment Market Share

Regional Analysis Preview

North America dominated the market in 2020, accounting for over 35.0% share of the global revenue. The market growth is due to factors such as the high prevalence of neuroblastoma in the region, established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth. In this region the United States has the maximum share due to supportive healthcare policies, a high number of patients, and a developed healthcare market. According to the American Cancer Society’s Cancer Statistics, nearly 800 new cases of neuroblastoma are reported in the United States every year. The above statistics prove that the high prevalence of the disease is boosting the market in the region.

Global Neuroblastoma Treatment Market Regional Analysis

Key Market Players & Competitive Landscape

Major market players in Neuroblastoma Therapy Market are United Therapeutics Corporation, Apeiron Biologics AG, Baxter, Cellectar Biosciences, Inc., Pfizer, Inc., MacroGenics, Inc., Bayer AG, Sun Pharmaceutical Industries, Inc., and Sartorius AG. Brief information about 10 companies will also be provided in the report. Similarly, growth strategies such as acquisition, merger, and expansion of the distribution network were few techniques adopted by most of companies providing neuroblastoma therapy market in recent years. For instance, on June 23, 2021, Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of neuroblastoma cancer. The FDA approved product DANYELZA is launched by the company which will benefit the neuroblastoma patients.

The Neuroblastoma Therapy Market is segmented as follows:

By Therapy

  • Surgery
  • Chemotherapy
  • Immunotherapy
  • Radiotherapy

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter No. 1 Introduction
    • 1.1. Report Description
      • 1.1.1. Purpose of the Report
      • 1.1.2. USP & Key Offerings
    • 1.2. Key Benefits for Stakehulders
    • 1.3. Target Audience
    • 1.4. Report Scope
  • Chapter No. 2 Executive Summary
    • 2.1. Key Findings
      • 2.1.1. Top Investment Pockets
        • 2.1.1.1. Market Attractiveness Analysis, By Therapy
        • 2.1.1.2. Market Attractiveness Analysis, By Distribution Channel
        • 2.1.1.3. Market Attractiveness Analysis, By Region
    • 2.2. Market Snapshot
    • 2.3. Global Neuroblastoma Treatment Market, 2016 – 2028 (USD Million)
    • 2.4. Insights from Primary Respondents
  • Chapter No. 3 COVID 19 Impact Analysis
    • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
      • 3.1.1. North America
      • 3.1.2. Europe
      • 3.1.3. Asia Pacific
      • 3.1.4. Latin America
      • 3.1.5. The Middle-East and Africa
    • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
    • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Million)
    • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
    • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
      • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
    • 3.6. Short Term Dynamics
    • 3.7. Long Term Dynamics
  • Chapter No. 4 Neuroblastoma Treatment Market – Therapy Segment Analysis
    • 4.1. Overview
      • 4.1.1. Market Revenue Share, By Therapy, 2020 & 2028
    • 4.2. Surgery
      • 4.2.1. Market Size and Forecast, By Region (USD Million)
      • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.3. Chemotherapy
      • 4.3.1. Market Size and Forecast, By Region (USD Million)
      • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.4. Immunotherapy
      • 4.4.1. Market Size and Forecast, By Region (USD Million)
      • 4.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.4.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.5. Radiotherapy
      • 4.5.1. Market Size and Forecast, By Region (USD Million)
      • 4.5.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.5.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 5 Neuroblastoma Treatment Market – Distribution Channel Segment Analysis
    • 5.1. Overview
      • 5.1.1. Market Revenue Share, By Distribution Channel, 2020 & 2028
    • 5.2. Hospital Pharmacies
      • 5.2.1. Market Size and Forecast, By Region (USD Million)
      • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.3. Retail Pharmacies
      • 5.3.1. Market Size and Forecast, By Region (USD Million)
      • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.4. Drug Stores
      • 5.4.1. Market Size and Forecast, By Region (USD Million)
      • 5.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.4.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 6 Neuroblastoma Treatment Market – Regional Analysis
    • 6.1. Overview
      • 6.1.1. Global Market Revenue Share, By Region, 2020 & 2028
      • 6.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Million)
    • 6.2. North America
      • 6.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 6.2.2. North America Market Revenue, By Therapy, 2016 – 2028
      • 6.2.3. North America Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.2.4. U.S.
        • 6.2.4.1. U.S. Market Revenue, By Therapy, 2016 – 2028
        • 6.2.4.2. U.S. Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.2.5. Canada
        • 6.2.5.1. Canada Market Revenue, By Therapy, 2016 – 2028
        • 6.2.5.2. Canada Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.2.6. Mexico
        • 6.2.6.1. Mexico Market Revenue, By Therapy, 2016 – 2028
        • 6.2.6.2. Mexico Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.3. Europe
      • 6.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 6.3.2. Europe Market Revenue, By Therapy, 2016 – 2028
      • 6.3.3. Europe Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.3.4. Germany
        • 6.3.4.1. Germany Market Revenue, By Therapy, 2016 – 2028
        • 6.3.4.2. Germany Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.3.5. France
        • 6.3.5.1. France Market Revenue, By Therapy, 2016 – 2028
        • 6.3.5.2. France Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.3.6. U.K.
        • 6.3.6.1. U.K. Market Revenue, By Therapy, 2016 – 2028
        • 6.3.6.2. U.K. Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.3.7. Italy
        • 6.3.7.1. Italy Market Revenue, By Therapy, 2016 – 2028
        • 6.3.7.2. Italy Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.3.8. Spain
        • 6.3.8.1. Spain Market Revenue, By Therapy, 2016 – 2028
        • 6.3.8.2. Spain Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.3.9. Rest of Europe
        • 6.3.9.1. Rest of Europe Market Revenue, By Therapy, 2016 – 2028
        • 6.3.9.2. Rest of Europe Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.4. Asia Pacific
      • 6.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 6.4.2. Asia Pacific Market Revenue, By Therapy, 2016 – 2028
      • 6.4.3. Asia Pacific Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.4.4. China
        • 6.4.4.1. China Market Revenue, By Therapy, 2016 – 2028
        • 6.4.4.2. China Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.4.5. Japan
        • 6.4.5.1. Japan Market Revenue, By Therapy, 2016 – 2028
        • 6.4.5.2. Japan Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.4.6. India
        • 6.4.6.1. India Market Revenue, By Therapy, 2016 – 2028
        • 6.4.6.2. India Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.4.7. South Korea
        • 6.4.7.1. South Korea Market Revenue, By Therapy, 2016 – 2028
        • 6.4.7.2. South Korea Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.4.8. South-East Asia
        • 6.4.8.1. South-East Asia Market Revenue, By Therapy, 2016 – 2028
        • 6.4.8.2. South-East Asia Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.4.9. Rest of Asia Pacific
        • 6.4.9.1. Rest of Asia Pacific Market Revenue, By Therapy, 2016 – 2028
        • 6.4.9.2. Rest of Asia Pacific Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.5. Latin America
      • 6.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 6.5.2. Latin America Market Revenue, By Therapy, 2016 – 2028
      • 6.5.3. Latin America Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.5.4. Brazil
        • 6.5.4.1. Brazil Market Revenue, By Therapy, 2016 – 2028
        • 6.5.4.2. Brazil Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.5.5. Argentina
        • 6.5.5.1. Argentina Market Revenue, By Therapy, 2016 – 2028
        • 6.5.5.2. Argentina Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.5.6. Rest of Latin America
        • 6.5.6.1. Rest of Latin America Market Revenue, By Therapy, 2016 – 2028
        • 6.5.6.2. Rest of Latin America Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.6. The Middle-East and Africa
      • 6.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 6.6.2. The Middle-East and Africa Market Revenue, By Therapy, 2016 – 2028
      • 6.6.3. The Middle-East and Africa Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.6.4. GCC Countries
        • 6.6.4.1. GCC Countries Market Revenue, By Therapy, 2016 – 2028
        • 6.6.4.2. GCC Countries Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.6.5. South Africa
        • 6.6.5.1. South Africa Market Revenue, By Therapy, 2016 – 2028
        • 6.6.5.2. South Africa Market Revenue, By Distribution Channel, 2016 – 2028
      • 6.6.6. Rest of Middle-East Africa
        • 6.6.6.1. Rest of Middle-East Africa Market Revenue, By Therapy, 2016 – 2028
        • 6.6.6.2. Rest of Middle-East Africa Market Revenue, By Distribution Channel, 2016 – 2028
  • Chapter No. 7 Neuroblastoma Treatment Market – Industry Analysis
    • 7.1. Introduction
    • 7.2. Market Drivers
      • 7.2.1. Driving Factor 1 Analysis
      • 7.2.2. Driving Factor 2 Analysis
    • 7.3. Market Restraints
      • 7.3.1. Restraining Factor Analysis
    • 7.4. Market Opportunities
      • 7.4.1. Market Opportunity Analysis
    • 7.5. Porter’s Five Forces Analysis
    • 7.6. PEST Analysis
    • 7.7. Regulatory Landscape
    • 7.8. Technology Landscape
    • 7.9. Regional Market Trends
      • 7.9.1. North America
      • 7.9.2. Europe
      • 7.9.3. Asia Pacific
      • 7.9.4. Latin America
      • 7.9.5. The Middle-East and Africa
    • 7.10. Pricing Analysis
    • 7.11. Value Chain Analysis
    • 7.12. Downstream Buyers
    • 7.13. Distributors/Traders List
  • Chapter No. 8 Competitive Landscape
    • 8.1. Company Market Share Analysis – 2019
      • 8.1.1. Global Neuroblastoma Treatment Market: Company Market Share, 2019
      • 8.1.2. Global Neuroblastoma Treatment Market, Company Market Revenue, 2016 – 2019 (USD Million)
      • 8.1.3. Global Neuroblastoma Treatment Market, Company Y-o-Y Growth, 2017 – 2019 (%)
      • 8.1.4. Global Neuroblastoma Treatment Market: Radar Determinant Chart, 2019
    • 8.2. Strategic Developments
      • 8.2.1. Acquisitions & Mergers
      • 8.2.2. New Product Launch
      • 8.2.3. Regional Expansion
    • 8.3. Company Strategic Developments – Heat Map Analysis
  • Chapter No. 9 Company Profiles
    • 9.1. United Therapeutics Corporation
      • 9.1.1. Company Overview
      • 9.1.2. Key Executives
      • 9.1.3. Product Portfolio
      • 9.1.4. Financial Overview
      • 9.1.5. Operating Business Segments
      • 9.1.6. Business Performance
      • 9.1.7. Recent Developments
    • 9.2. Apeiron Biulogics AG
    • 9.3. Baxter
    • 9.4. Cellectar Biosciences, Inc.
    • 9.5. Pfizer, Inc.
    • 9.6. MacroGenics, Inc.
    • 9.7. Bayer AG
    • 9.8. Sun Pharmaceutical Industries, Inc.
    • 9.9. Sartorius AG
  • Chapter No. 10 Marketing Strategy Analysis
    • 10.1. Marketing Channel
    • 10.2. Direct Marketing
    • 10.3. Indirect Marketing
    • 10.4. Marketing Channel Development Trends
    • 10.5. Economic/Pulitical Environmental Change
  • Chapter No. 11 Research Methodology
    • 11.1. Research Methodology
    • 11.2. Phase I - Secondary Research
    • 11.3. Phase II - Data Modeling
      • 11.3.1. Company Share Analysis Model
      • 11.3.2. Revenue Based Modeling
    • 11.4. Phase III - Primary Research
    • 11.5. Research Limitations
      • 11.5.1. Assumptions

List of Figures 

FIG NO. 1. Market Attractiveness Analysis, By Component
FIG NO. 2. Market Attractiveness Analysis, By Application
FIG NO. 3. Market Attractiveness Analysis, By End Use Industry
FIG NO. 4. Market Attractiveness Analysis, By Region
FIG NO. 5. Global Neuroblastoma Treatment Market Revenue, 2016 – 2028 (USD Million)
FIG NO. 6. Impact of COVID-19 Pandemic in North American Countries
FIG NO. 7. Market Revenue Share, By Component, 2020 & 2028
FIG NO. 8. Global Neuroblastoma Treatment Market for Software, Revenue (USD Million) 2016 – 2028
FIG NO. 9. Comparative Revenue Analysis of Neuroblastoma Treatment Market for Software, By Country, 2020 & 2028
FIG NO. 10. Global Neuroblastoma Treatment Market for Service, Revenue (USD Million) 2016 – 2028
FIG NO. 11. Comparative Revenue Analysis of Neuroblastoma Treatment Market for Service, By Country, 2020 & 2028
FIG NO. 12. Global Neuroblastoma Treatment Market Revenue Share, By Application, 2020 & 2028
FIG NO. 13. Global Neuroblastoma Treatment Market for Marketing, Revenue (USD Million) 2016 – 2028
FIG NO. 14. Comparative Revenue Analysis of Neuroblastoma Treatment Market for Marketing, By Country, 2020 & 2028
FIG NO. 15. Global Neuroblastoma Treatment Market for Operations, Revenue (USD Million) 2016 – 2028
FIG NO. 16. Comparative Revenue Analysis of Neuroblastoma Treatment Market for Operations, By Country, 2020 & 2028
FIG NO. 17. Global Neuroblastoma Treatment Market for Finance, Revenue (USD Million) 2016 – 2028
FIG NO. 18. Comparative Revenue Analysis of Neuroblastoma Treatment Market for Finance, By Country, 2020 & 2028
FIG NO. 19. Global Neuroblastoma Treatment Market for Human Resource, Revenue (USD Million) 2016 – 2028
FIG NO. 20. Comparative Revenue Analysis of Neuroblastoma Treatment Market for Human Resource, By Country, 2020 & 2028
FIG NO. 21. Global Neuroblastoma Treatment Market for Others, Revenue (USD Million) 2016 – 2028
FIG NO. 22. Comparative Revenue Analysis of Neuroblastoma Treatment Market for Others, By Country, 2020 & 2028
FIG NO. 23. Global Neuroblastoma Treatment Market Revenue Share, By End Use Industry, 2020 & 2028
FIG NO. 24. Global Neuroblastoma Treatment Market for Manufacturing, Revenue (USD Million) 2016 – 2028
FIG NO. 25. Comparative Revenue Analysis of Neuroblastoma Treatment Market for Manufacturing, By Country, 2020 & 2028
FIG NO. 26. Global Neuroblastoma Treatment Market for Hospitality, Revenue (USD Million) 2016 – 2028
FIG NO. 27. Comparative Revenue Analysis of Neuroblastoma Treatment Market for Hospitality, By Country, 2020 & 2028
FIG NO. 28. Global Neuroblastoma Treatment Market for BFSI, Revenue (USD Million) 2016 – 2028
FIG NO. 29. Comparative Revenue Analysis of Neuroblastoma Treatment Market for BFSI, By Country, 2020 & 2028
FIG NO. 30. Global Neuroblastoma Treatment Market for Retail, Revenue (USD Million) 2016 – 2028
FIG NO. 31. Comparative Revenue Analysis of Neuroblastoma Treatment Market for Retail, By Country, 2020 & 2028
FIG NO. 32. Global Neuroblastoma Treatment Market for IT & Telecom, Revenue (USD Million) 2016 – 2028
FIG NO. 33. Comparative Revenue Analysis of Neuroblastoma Treatment Market for IT & Telecom, By Country, 2020 & 2028
FIG NO. 34. Global Neuroblastoma Treatment Market for Others, Revenue (USD Million) 2016 – 2028
FIG NO. 35. Comparative Revenue Analysis of Neuroblastoma Treatment Market for Others, By Country, 2020 & 2028
FIG NO. 36. Global Neuroblastoma Treatment Market Revenue Share, By Region, 2020 & 2028
FIG NO. 37. North America Neuroblastoma Treatment Market Revenue, 2016 - 2028 (USD Million)
FIG NO. 38. Porter’s Five Forces Analysis for Global Neuroblastoma Treatment Market
FIG NO. 39. PEST Analysis for Global Neuroblastoma Treatment Market
FIG NO. 40. Pricing Analysis for Global Neuroblastoma Treatment Market
FIG NO. 41. Value Chain Analysis for Global Neuroblastoma Treatment Market
FIG NO. 42. Company Share Analysis, 2019
FIG NO. 43. Radar Determinant Chart, 2019
FIG NO. 44. Company Strategic Developments – Heat Map Analysis
FIG NO. 45. Oracle Corporation Business Segment Revenue Share, 2020 (%)
FIG NO. 46. Oracle Corporation Geographical Segment Revenue Share, 2020 (%)
FIG NO. 47. Market Channels
FIG NO. 48. Marketing Channel Development Trend
FIG NO. 49. Growth in World Gross Product, 2008-2018
FIG NO. 50. Research Methodology – Detailed View
FIG NO. 51. Research Methodology 
 


List Of Tables 

TABLE NO. 1. Global Neuroblastoma Treatment Market: Snapshot
TABLE NO. 2. Quarterly Neuroblastoma Treatment Market Revenue by Region, 2020
TABLE NO. 3. Quarterly Neuroblastoma Treatment Market Revenue Forecast by Region, 2021
TABLE NO. 4. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Million)
TABLE NO. 5. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
TABLE NO. 6. Global Neuroblastoma Treatment Market for Software, by Region, 2016 – 2028 (USD Million)
TABLE NO. 7. Global Neuroblastoma Treatment Market for Service, by Region, 2016 – 2028 (USD Million)
TABLE NO. 8. Global Neuroblastoma Treatment Market for Marketing, by Region, 2016 – 2028 (USD Million)
TABLE NO. 9. Global Neuroblastoma Treatment Market for Operations, by Region, 2016 – 2028 (USD Million)
TABLE NO. 10. Global Neuroblastoma Treatment Market for Finance, by Region, 2016 – 2028 (USD Million)
TABLE NO. 11. Global Neuroblastoma Treatment Market for Human Resource, by Region, 2016 – 2028 (USD Million)
TABLE NO. 12. Global Neuroblastoma Treatment Market for Others, by Region, 2016 – 2028 (USD Million)
TABLE NO. 13. Global Neuroblastoma Treatment Market for Manufacturing, by Region, 2016 – 2028 (USD Million)
TABLE NO. 14. Global Neuroblastoma Treatment Market for Hospitality, by Region, 2016 – 2028 (USD Million)
TABLE NO. 15. Global Neuroblastoma Treatment Market for BFSI, by Region, 2016 – 2028 (USD Million)
TABLE NO. 16. Global Neuroblastoma Treatment Market for Retail, by Region, 2016 – 2028 (USD Million)
TABLE NO. 17. Global Neuroblastoma Treatment Market for IT & Telecom, by Region, 2016 – 2028 (USD Million)
TABLE NO. 18. Global Neuroblastoma Treatment Market for Others, by Region, 2016 – 2028 (USD Million)
TABLE NO. 19. Global Neuroblastoma Treatment Market Revenue, By Region, 2016 – 2028 (USD Million)
TABLE NO. 20. North America Neuroblastoma Treatment Market Revenue, By Country, 2016 – 2028 (USD Million)
TABLE NO. 21. North America Neuroblastoma Treatment Market Revenue, By Component, 2016 – 2028 (USD Million)
TABLE NO. 22. North America Neuroblastoma Treatment Market Revenue, By Application, 2016 – 2028 (USD Million)
TABLE NO. 23. North America Neuroblastoma Treatment Market Revenue, By End Use Industry, 2016 – 2028 (USD Million)
TABLE NO. 24. U.S. Neuroblastoma Treatment Market Revenue, By Component, 2016 – 2028 (USD Million)
TABLE NO. 25. U.S. Neuroblastoma Treatment Market Revenue, By Application, 2016 – 2028 (USD Million)
TABLE NO. 26. U.S. Neuroblastoma Treatment Market Revenue, By End Use Industry, 2016 – 2028 (USD Million)
TABLE NO. 27. Canada Neuroblastoma Treatment Market Revenue, By Component, 2016 – 2028 (USD Million)
TABLE NO. 28. Canada Neuroblastoma Treatment Market Revenue, By Application, 2016 – 2028 (USD Million)
TABLE NO. 29. Canada Neuroblastoma Treatment Market Revenue, By End Use Industry, 2016 – 2028 (USD Million)
TABLE NO. 30. Mexico Neuroblastoma Treatment Market Revenue, By Component, 2016 – 2028 (USD Million)
TABLE NO. 31. Mexico Neuroblastoma Treatment Market Revenue, By Application, 2016 – 2028 (USD Million)
TABLE NO. 32. Mexico Neuroblastoma Treatment Market Revenue, By End Use Industry, 2016 – 2028 (USD Million)
TABLE NO. 33. Drivers for the Neuroblastoma Treatment Market: Impact Analysis
TABLE NO. 34. Restraints for the Neuroblastoma Treatment Market: Impact Analysis
TABLE NO. 35. Major Buyers of Neuroblastoma Treatment
TABLE NO. 36. Distributors/Traders List of Neuroblastoma Treatment
TABLE NO. 37. Global Neuroblastoma Treatment Market, Company Market Revenue, 2016 – 2019 (USD Million)
TABLE NO. 38. Global Neuroblastoma Treatment Market, Company Y-o-Y Growth, 2017 – 2019 (USD Million)
 


 

Methodology

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

The Neuroblastoma Treatment market was valued at USD 437.1 Million in 2020.
The Neuroblastoma Treatment market is expected to reach USD 600.5 Million by 2028, growing at a CAGR of 4.1% between 2021 to 2028.
Neuroblastoma happens when immature nerve tissues (neuroblasts) grow out of control. The cells become abnormal and continue growing and dividing, forming a tumor. A genetic mutation (a change in the neuroblast’s genes) causes the cells to grow and divide uncontrollably. Healthcare providers are not sure what causes the genetic mutation and still there is no technology to find the main cause for this cancer to grow. Due to this reason the need for the treatment is necessary and government bodies and healthcare companies are investing funds for research and development for this treatment. This is some of thre prominent reasons for the growth for neuroblastoma treatment market.
North America dominated the market in 2020, accounting for over 35.0% share of the global revenue. The market growth is due to factors such as the high prevalence of neuroblastoma in the region, established healthcare infrastructure are some of the key factors accountable for its large share in the market.
Major Market players in Neuroblastoma Therapy Market are United Therapeutics Corporation, Apeiron Biologics AG, Baxter, Cellectar Biosciences, Inc., Pfizer, Inc., MacroGenics, Inc., Bayer AG, Sun Pharmaceutical Industries, Inc., and Sartorius AG.

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed